Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore

Kenneth Hughes, Tar-Choon Aw, Ponnudurai Kuperan, Maurice Choo

Abstract

Study objective—To examine the hypothesis that the higher rates of coronary heart disease (CHD) in Indians (South Asians) compared with Malays and Chinese is at least partly explained by central obesity, insulin resistance, and syndrome X (including possible components).

Design—Cross sectional study of the general population.

Setting—Singapore.

Participants—Random sample of 961 men and women (Indians, Malays, and Chinese) aged 30 to 69 years.

Main results—Fasting serum insulin concentration was correlated directly and strongly with body mass index (BMI), waist-hip ratio (WHR), and abdominal diameter. The fasting insulin concentration was correlated inversely with HDL cholesterol and directly with the fasting triglyceride concentration, blood pressures, plasminogen activator inhibitor 1 (PAI-1), and tissue plasminogen activator (tPA), but it was not correlated with LDL cholesterol, apolipoproteins B and A1, lipoprotein(a) (Lp(a)), fibrinogen, factor VIIc, or prothrombin fragment (F)1+2. This indicates that the former but not the latter are part of syndrome X. While Malays had the highest BMI, Indians had a higher WHR (men 0.93 and women 0.84) than Malays (men 0.91 and women 0.82) and Chinese (men 0.90 and women 0.82). In addition, Indians had higher fasting insulin values and more glucose intolerance than Malays and Chinese. Indians had lower HDL cholesterol, and higher PAI-1, tPA, and Lp(a), but not higher LDL cholesterol, fasting triglyceride, blood pressures, fibrinogen, factor VIIc, or prothrombin F1+2.

Conclusions—Indians are more prone than Malays or Chinese to central obesity with insulin resistance and glucose intolerance and there are no apparent environmental reasons for this in Singapore. As a consequence, Indians develop some but not all of the features of syndrome X. They also have higher Lp(a) values. All this puts Indians at increased risk of atherosclerosis and thrombosis and must be at least part of the explanation for their higher rates of CHD.

(J Epidemiol Community Health 1997;51:394–399)

Indians or South Asians (ie, persons from the Indian subcontinent) have been found in a number of countries to be particularly susceptible to coronary heart disease (CHD). It has been shown, however, that this is not a result of the classic risk factors of cigarette smoking, hypertension, and increased low density lipoprotein (LDL) cholesterol.

Insulin resistance, which leads to hyperinsulinaemia and is associated with centralised adiposity (preferential deposition of adipose tissue on the trunk and intra-abdominally), has been related to both diabetes and CHD and is a possible mechanism for high rates of both diseases in Indians. Syndrome X (Reaven's or insulin resistance syndrome) is characterised by increased insulin resistance, glucose intolerance, hypertension, and dyslipidaemia with high fasting triglyceride and low high density lipoprotein (HDL) cholesterol concentrations. A higher frequency of this syndrome related to central obesity has been reported in Indians. It has been found in Britain, both in London and to some extent, though not completely, in Bradford. However, these comparisons were with white people and differences in the components of the syndrome may not be the same when Indians are compared with other Asians.

Syndrome X is being expanded and has recently been called the "athero-thrombogenic syndrome" showing both atherosclerotic and thrombotic components. It can include increased plasminogen activator inhibitor type 1 (PAI-1), and possibly other haemostatic factors. There has been increasing interest in the role of haemostatic factors in the aetiology of CHD. Lipoprotein(a) (Lp(a)) has LDL-like properties that increase atherosclerosis. In addition, Lp(a), which is structurally similar to plasminogen, inhibits plasminogen binding to the endothelial cell, thus interfering with plasmin generation, and promotes endothelial cell synthesis of PAI-1, which inhibits tissue plasminogen activator (tPA) and hence reduces fibrinolysis. Lp(a) is therefore both atherogenic and thrombogenic.

Singapore is an island state with a population of 3.3 million people composed of Chinese 76%, Malays 14%, Indians 7%, and "others" 3% whose origins have been described. Of the Indians, 80% originate from the southern states of India (Tamil Nadu and Kerala) and Sri Lanka. Singapore has undergone rapid economic development over the last three decades and the commonest causes of death are now cardiovascular diseases and cancers. Mortality
rates from CHD are highest in Indians then Malays and then Chinese for both genders. A population based survey (the Singapore thyroid and heart study) found that, as elsewhere, Indians did not have higher cigarette smoking rates, blood pressures, or LDL cholesterol concentrations but did have more diabetes and lower HDL cholesterol values. The National University of Singapore heart study is a further population based survey of cardiovascular risk factors, including the newer ones not studied previously. One of its objectives is to identify reasons for the increased susceptibility of Indians to CHD. This paper examines central obesity, insulin resistance, and syndrome X (including possible components).

Methods

SAMPLE

This cross sectional survey was of a random sample of persons aged 30 to 69 years from the general population of Singapore. The sample was obtained from two sources—the thyroid and heart study, and electoral registers of five divisions, each in a different part of the island (north, south, east, west, and centre). There was disproportionate sampling in relation to ethnic groups to obtain equal numbers of subjects in each of the six gender-ethnic groups. The required sample was 180 subjects in each gender-ethnic group giving a total of 1080 subjects. Assuming that 20% of the subjects would not be recruitable because of death, migration, infirmity, or relocation (which is high in Singapore due to massive urban redevelopment), and assuming a response rate of 75%, a total of 1800 persons was selected. Of these, 419 (23.3%) were not recruitable and 983 responded, giving a response rate of 71.2%. Of the 983 subjects, 22 were 70 years or over and were excluded, leaving 961 persons aged between 30 and 69 years.

PROCEDURES

Morning clinics were held from June 1993 to December 1995, with both genders and three ethnic groups seen concurrently. Subjects were asked to fast from 21.00 hours the previous evening. Questionnaires were administered by a nurse trained in interview techniques with questions on age, gender, ethnic group (classification previously described), occupation, exercise, cigarette smoking, and alcohol consumption. Anthropometric measurements were carried out by a nurse trained in the techniques. Height (to the nearest 0.1 cm) and weight (to the nearest 0.1 kg) were measured on a SECA machine without shoes and in light clothing after emptying all pockets. Waist circumference (smallest measurement between the costal margins and the iliac crests) and hip circumference (at the level of the greater trochanters) were measured with a tape to the nearest 0.5 cm with the subject standing. Intra-abdominal fat mass was assessed by measuring the abdominal diameter at the level of the iliac crests with a ruler and tape to the nearest 0.5 cm with the subject lying supine.

Blood pressures were taken using the standard mercury sphygmomanometer. The same doctor (KH) did the measuring to remove inter-observer variation, and it was carried out according to the MONICA project protocol to reduce intra-observer variation. Measurement took place between 09.00 and 11.00 hours to remove diurnal variation. Phases 1 and 5 were recorded and the mean of two readings used for the analyses. All subjects were assessed by the same doctor (KH) who made a diagnosis of hypertension if the person was on current antihypertensive medication or had systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 95 mmHg.

Venous blood samples were taken with the subject in a sitting position. Venous vacuum containers with minimal venous stasis were used. Venepuncture took place between 10.00 and 12.00 hours to remove diurnal variation, and after at least 10 minutes rest. All measurements were made in the Department of Laboratory Medicine, National University Hospital. The first two specimens were collected in plain vacutainers and serum was analysed within 1 hour. Lipids were measured enzymatically on an autoanalyser (Ektachem, Kodak)—total cholesterol and triglyceride directly and HDL cholesterol after precipitation, with LDL cholesterol calculated from the Friedewald formula. Measurements of apolipoproteins (Apo) B and A1 were by immunonephelometry on the Beckman Array and determination of Lp(a) was by enzyme immunoassay using Abbott IMX. Fasting serum insulin was used as an index of insulin resistance as the hyperinsulinaemic euglycaemic clamp and the insulin suppression test are not suitable for epidemiological surveys.

The third and fourth specimens of blood were collected in citrated vacutainers (4.5 ml of blood and 0.5 ml of 3.2% trisodium citrate). The blood was immediately double spun at 3000 g for 15 minutes each time and platelet free plasma was removed. Fibrinogen and factor VIIc were measured within two hours, the former by the turbidimetric method on the
Table 1 Pearson partial correlation coefficients adjusted for age (significance level, p) between serum insulin and other factors for fasting subjects in relation to gender and ethnic group in people aged 30 to 69 years*

<table>
<thead>
<tr>
<th>Factor</th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Indians (n = 137)</td>
<td>Malays (n = 122)</td>
</tr>
<tr>
<td>Body mass index</td>
<td>0.53 (&lt;0.01)</td>
<td>0.61 (&lt;0.01)</td>
</tr>
<tr>
<td>Waist-hip ratio</td>
<td>0.33 (&lt;0.01)</td>
<td>0.32 (&lt;0.01)</td>
</tr>
<tr>
<td>Abdominal diameter</td>
<td>0.44 (&lt;0.01)</td>
<td>0.64 (&lt;0.01)</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>0.14 (0.09)</td>
<td>0.31 (&lt;0.01)</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>0.22 (&lt;0.01)</td>
<td>0.32 (&lt;0.01)</td>
</tr>
<tr>
<td>Serum LDL cholesterol</td>
<td>-0.03 (0.73)</td>
<td>-0.06 (0.46)</td>
</tr>
<tr>
<td>Serum triglyceride</td>
<td>-0.14 (0.10)</td>
<td>-0.10 (0.25)</td>
</tr>
<tr>
<td>Serum apolipoprotein A</td>
<td>0.21 (0.01)</td>
<td>0.12 (0.19)</td>
</tr>
<tr>
<td>Serum apolipoprotein B</td>
<td>0.12 (0.15)</td>
<td>0.12 (0.17)</td>
</tr>
<tr>
<td>Serum apolipoprotein A1</td>
<td>-0.07 (0.42)</td>
<td>-0.17 (0.06)</td>
</tr>
<tr>
<td>Plasma PAI-1</td>
<td>-0.09 (0.02)</td>
<td>-0.25 (&lt;0.01)</td>
</tr>
<tr>
<td>Plasma tPA antigen</td>
<td>0.21 (0.01)</td>
<td>0.42 (0.01)</td>
</tr>
<tr>
<td>Plasma fibrinogen</td>
<td>0.27 (&lt;0.01)</td>
<td>0.47 (0.01)</td>
</tr>
<tr>
<td>Plasma fibrinogen</td>
<td>0.12 (0.17)</td>
<td>0.16 (0.08)</td>
</tr>
<tr>
<td>Plasma factor VIIc</td>
<td>-0.01 (0.88)</td>
<td>0.21 (0.01)</td>
</tr>
<tr>
<td>Plasma prothrombin fragment 1 + 2</td>
<td>-0.12 (0.16)</td>
<td>-0.13 (0.14)</td>
</tr>
</tbody>
</table>

LDL = low density lipoprotein, HDL = high density lipoprotein, PAI-1 = plasminogen activator inhibitor 1, tPA = tissue plasminogen activator.

*Excludes diabetes on treatment.

DuPont aca analyser and the latter by the one stage clotting assay on the Cobas fibrometer (Roche Diagnostic). Aliquots of plasma were kept frozen at −70°C for subsequent measurement in batches. The prothrombin fragment (F)1 + 2 (which indicates thrombin formation and therefore activation of the coagulation system) was determined using ELISA kits from Behring (Enzygnost F1 + 2) and PAI-1 and tPA were measured by ELISA kits from Diagnostica Stago, France.

The fifth specimen was 2 ml of blood collected in a fluoride oxalate vacutainer with plasma glucose measured within 1 hour by specific enzyme assay on the Kodak Analyser. Subjects with a glucose concentration ≥ 5.5 mmol/l who were not currently on medication for diabetes, subsequently had an oral glucose tolerance test (after at least 10 hours fasting) of 75 g of dextrose in 296 ml of carbonated orange (Trutol 75, Custom Laboratories Inc, USA). They then had measurements of plasma glucose at fasting and 2 hours after the oral glucose. They were classified according to the results of their 2-hour glucose concentration as having diabetes (≥11.1 mmol/l), impaired glucose tolerance (7.8 to <11.1 mmol/l), or normal (<7.8 mmol/l). Those with a fasting plasma glucose concentration < 5.5 mmol/l are very unlikely to have diabetes. Subjects currently taking medication for diabetes were also classified as diabetic. Of the diabetics, only two (both Chinese women less than 40 years) were insulin dependent and so the analysis is of non-insulin dependent diabetes mellitus (NIDDM). A classification of glucose intolerance was made with either diabetes or impaired glucose tolerance.

**Analysis**

The mean ages were very similar in relation to gender and ethnic group These were as follows: Indians, men 46.8 and women 45.8 years; Malays, men 46.7 and women 46.1 years; and Chinese, men 46.9 and women 46.7 years. Nevertheless, age adjustment was performed. Pearson product moment partial correlation coefficients (after adjusting for age) between serum insulin and other factors were calculated using SPSS software. Age adjustment for mean was by analysis of covariance using the GLM procedure of SAS and for prevalences by direct standardisation to the total population of the sample with significance testing by the Z test. All significance testing was two tailed. Only subjects who had fasted at least 10 hours (96.8% of the total) were used in the analyses of triglyceride and insulin, and also of PAI-1 and tPA (as lipaemia can affect measurement of the fibrinolytic system). For insulin measurements, diabetics on treatment were excluded.

**Results**

**Correlations between fasting serum insulin and other factors (Table 1)**

For all six gender-ethnic groups, the fasting insulin value was strongly and directly correlated with body mass index (BMI), waist-hip ratio (WHR), and abdominal diameter, least strongly with WHR (see table 1). There were direct correlations with systolic and diastolic blood pressures. There were no correlations with LDL cholesterol but inverse correlation with HDL cholesterol and direct ones with fasting triglyceride values. There were no important correlations with Apo B or Apo A1, and while all correlations with Lp(a) were inverse some of the coefficients were small and statistically insignificant. Fasting insulin was strongly and directly correlated with PAI-1 and tPA. There was a direct and statistically significant correlation with fibrinogen in some but not all groups and no evidence at all of correlations with factor VIIc and prothrombin F1 + 2.

**Mean levels and prevalences of factors**

Mean BMI was higher in women than men for Indians and Malays (tables 2 and 3) but the same for Chinese. For both genders BMI was highest in Malays, then Indians and then Chinese. Mean WHRs (higher in men than women) were highest in Indians for both genders; in men Malays had a slightly higher rate than Chinese, while in women there was no
Table 2  Means and prevalences (95% confidence intervals) of factors for Indians (I), Malays (M) and Chinese (C), men age adjusted* for age group 30 to 69 years

<table>
<thead>
<tr>
<th>Factor</th>
<th>Indians (n = 170)</th>
<th>Malays (n = 147)</th>
<th>Chinese (n = 161)</th>
<th>Significance level, p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I v M</td>
<td>I v C</td>
<td>M v C</td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24.2 (23.6, 24.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist-hip ratio</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.93 (0.89, 0.97)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal diameter (cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22.7 (23.3, 23.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting serum insulin (mU/l)†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6 (7.5, 9.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose intolerance (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27.8 (19.9, 35.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>130 (127, 133)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>82 (80, 84)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.7 (13.0, 27.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum LDL cholesterol (mmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.0 (3.9, 4.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum HDL cholesterol (mmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.73 (0.70, 0.76)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting serum triglyceride (mmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.8 (1.7, 1.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum apolipoprotein B (mg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>128 (123, 133)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum apolipoprotein A1 (mg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>127 (124, 130)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum lipoprotein(a) (mg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.1 (15.6, 20.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma PAI-1 (ng/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26.7 (24.3, 26.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma fibrinogen (g/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.7 (2.6, 2.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma factor VIIc (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.26 (1.20, 1.32)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma prothrombin F1 + 2 (nmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 (1.4, 1.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PAI = plasminogen activator inhibitor, IPA = tissue plasminogen activator.
* By analysis of covariance for means and direct standardisation for prevalences.
† Excludes diabetics on treatment.

Table 3  Means and prevalences (95% confidence intervals) of factors for Indians (I), Malays (M) and Chinese (C), women age adjusted* for age group 30 to 69 years

<table>
<thead>
<tr>
<th>Factor</th>
<th>Indians (n = 172)</th>
<th>Malays (n = 142)</th>
<th>Chinese (n = 161)</th>
<th>Significance level, p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I v M</td>
<td>I v C</td>
<td>M v C</td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26.2 (25.6, 26.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist-hip ratio</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.84 (0.83, 0.85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal diameter (cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22.4 (22.0, 22.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting serum insulin (mU/l)†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1 (8.2, 10.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose intolerance (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.3 (13.5, 27.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>135 (132, 138)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>79 (77, 81)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.6 (12.9, 26.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum LDL cholesterol (mmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.0 (3.9, 4.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum HDL cholesterol (mmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.88 (0.85, 0.91)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting serum triglyceride (mmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 (1.4, 1.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum apolipoprotein B (mg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>120 (115, 125)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum lipoprotein(a) (mg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>138 (135, 141)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma PAI-1 (ng/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29.5 (26.8, 32.2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma fibrinogen (g/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2 (8.9, 9.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma factor VIIc (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>139 (133, 145)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma prothrombin F1 + 2 (nmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.7 (1.6, 1.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PAI = plasminogen activator inhibitor, IPA = tissue plasminogen activator.
* By analysis of covariance for means and direct standardisation for prevalences.
† Excludes diabetics on treatment.

Difference. Abdominal diameter (similar in both genders for Indians and Malays but higher in men than women for Chinese) was higher in Indians and Malays than Chinese for both genders.

Fasting insulin values were higher in women than in men and for both genders were higher in Indians; Malays had higher levels than Chinese but the differences were not statistically significant. The prevalence of glucose intolerance was highest in Indians, then Malays, and then Chinese for men, while for women it was virtually the same in Indians and Malays, with both having higher prevalences than Chinese. Blood pressure levels in relation to ethnicity group were similar for men and slightly higher in Malays for women, with no ethnic differences in prevalences of hypertension for both genders.

Mean LDL cholesterol concentrations (similar in the two genders) were similar in the three ethnic groups for both genders. However, HDL cholesterol values (higher in women than men) were highest in Chinese, then in Malays, and then in Indians for both genders. Fasting triglyceride concentrations (higher in men than women) were slightly higher in Indians and Malays than in Chinese but the differences were not statistically significant. Apo B values (similar in both genders) were lower in Chinese than in Indians and Malays but the differences were only statistically significant in men. Apo AI values (higher in women than men) were highest in Chinese, then in Malays, and then in Indians for both genders. As in studies elsewhere, all six distributions of Lp(a) were skewed to the right. Serum Lp(a) was higher in women than men, and for both genders concentrations were higher in Indians than Malates and Chinese, which showed no differences.

There was little gender difference in PAI-1 levels. These were higher in Indians than in Chinese and Malays (though for men the difference with Malays was not statistically significant). With regard to TPA levels (higher in men than women), these were highest in Indians, then Malays and then Chinese, for both genders. Fibrinogen values were higher in women than men, and while there were some statistically significant ethnic differences there was no consistency, with concentrations highest.
in Malays for men and in Indians for women. Both factor VIIc and prothrombin F1 + 2 levels were higher in women than men, and the only ethnic differences were for women, with Malays having slightly higher concentrations.

Discussion
Correlations between fasting serum insulin and other risk factors are consistent across the six groups, showing that syndrome X operates similarly in both genders and in the three ethnic groups. Fasting insulin is strongly correlated with obesity, more strongly for BMI than WHR as has been found elsewhere.\(^ {17} \) The reason for this is not clear. However insulin is as strongly correlated with abdominal diameter (measured as a measure of abdominal or visceral fat) as BMI.

Those cardiovascular risk factors that are strongly and consistently correlated with fasting insulin (blood pressures, HDL cholesterol, fasting triglyceride, PAI-1, and tPA) are identified as components of syndrome X, while those factors that are not correlated with fasting insulin (LDL cholesterol, Apo B, Apo A1, Lp(a), fibrinogen, factor VIIc, and prothrombin F1 + 2) are not identified as components of syndrome X. Syndrome X increases the risk of atherosclerosis and thrombosis, the latter from reduced fibrinolytic activity due to increased PAI-1.

In Singapore, WHRs in male Indians are lower than values in London,\(^ {6} \) but the same as those in Bradford.\(^ {7} \) For women the values are the same as in London.\(^ {6} \) In both genders Malays tend to develop generalised obesity (measured by BMI), while Indians preferentially develop central obesity (measured by WHR). Furthermore, Indians have higher fasting insulin levels. Hence, Indians are more prone than Malays and Chinese to develop the central obesity-insulin resistance syndrome. While this syndrome can have genetic and environmental causes,\(^ {18} \) there are no apparent environmental differences other than diet among the ethnic groups in Singapore. It has been postulated that it is more pronounced in Indians because of low physical activity and high energy intake in a population adapted to survival under conditions of unreliable food supply and physically demanding work.\(^ {4} \) Against this explanation for the findings among Indians in Singapore is the fact that the Chinese have also come from such a background and Malays have higher general obesity levels than Indians. There is no evidence in Singapore that Indians have lower levels of physical activity than Malays or Chinese.\(^ {19} \)

Whether hyperinsulinaemia in Indians can itself lead to increased CHD is not clear. It has been argued that the relation between hyperinsulinaemia and CHD is due to related risk factors,\(^ {20} \) but a recent study found hyperinsulinaemia to be an independent risk factor.\(^ {21} \)

Ethnic differences in glucose intolerance are the same as in the previous survey.\(^ {13} \) The high prevalence of glucose intolerance in Malay women no doubt results from their high levels of obesity. More glucose intolerance will contribute to Indians' higher risk of CHD and to the higher risk of Malays compared with Chinese.

No important ethnic differences in blood pressures and hypertension were found, as in the previous survey\(^ {11} \) and another survey in Singapore.\(^ {22} \) The finding that Indians do not have higher blood pressures is further indicated by the fact that they do not have higher mortality than the other two ethnic groups from cerebrovascular disease,\(^ {12} \) for which hypertension is the main risk factor. While studies vary on this, it has been pointed out that while Indians have relatively high CHD mortality, they do not usually have a higher prevalence of hypertension than other ethnic groups.\(^ {23} \) The relationship between insulin resistance and hypertension is controversial,\(^ {24} \) with evidence that it may differ in relation to ethnic group.\(^ {25} \)

No ethnic differences have been found for LDL cholesterol (as in the previous survey,\(^ {11} \)), while, for men, the slightly higher levels of Apo B in Indians and Malays than in Chinese have also been reported previously.\(^ {20} \) Ethnic differences in HDL cholesterol are the same as in the previous study.\(^ {11} \) What is not clear is why Indians do not have higher fasting triglyceride concentrations. However, compared with Europeans, Indians had higher fasting triglyceride in one London study,\(^ {6} \) levels that were only slightly higher in Bradford,\(^ {7} \) and levels that were lower in another survey in London,\(^ {23} \) despite lower levels of HDL cholesterol in Indians in all three surveys.

The finding of higher Lp(a) levels in Indians is consistent with findings elsewhere.\(^ {5} \) At least 70% of the variation in Lp(a) levels in populations is considered genetic,\(^ {26} \) suggesting the reason for higher levels in Indians is at least partly genetic. A study in Singapore found evidence that the distributions of Apo(a) phenotypes (determined by the genotypes) would give higher Lp(a) levels in Indians than in Malays and Chinese but also that the Apo(a) type-specific Lp(a) levels were higher in Indians than in Chinese and Malays suggesting that other unknown factors besides the Apo(a) electromorphs account for the differences in Lp(a) levels.\(^ {30} \) The small study size, however, precludes definite conclusions.\(^ {30} \) Whatever the reason, higher Lp(a) is a contributor to Indians' higher rates of CHD through an increased risk of atherosclerosis\(^ {10} \) and thrombosis,\(^ {11} \) and is probably a major determinant of CHD in young Indians.

Indians have higher PAI-1 levels than the other two ethnic groups, though in men the difference with Malays is not statistically significant. However, the fact that Indians do have higher PAI-1 levels is further shown by their
Central obesity, insulin resistance, syndrome X, and \( Lp(a) \) in Singapore

higher \( tPA \) levels, which show highly significant differences for all groups. Assays of \( tPA \) with immunochemical methods (as in this study) measure active and inactive \( tPA \). The latter is much the larger fraction and is composed of complexes with inhibitors, particularly PAI-1, so that the \( tPA \) antigen concentration largely reflects the PAI-1 concentration and an increase in PAI-1 leads to an increase in \( tPA \).\(^{21} \) Furthermore, there is evidence that high PAI-1 and \( tPA \) antigen levels increase the risk of CHD.\(^{21} \)\(^{31} \) Hence higher levels of PAI-1 and \( tPA \) are part of the explanation for Indians' higher risk of CHD. A relationship has been found between PAI-1 and insulin resistance,\(^{17} \)\(^{32} \) but whether higher levels of PAI-1 in Indians can be completely explained by hyperinsulinaemia or whether there are also other causes such as genetic ones is not clear. Higher levels of \( Lp(a) \) in Indians may help to increase PAI-1 and will accentuate its antifibrinolytic effect.\(^{17} \) Similar levels of fibrinogen, factor VIIc, and prothrombin \( F1+2 \) indicate no ethnic differences in coagulation.

In conclusion, this study in Singapore has shown that Indians are more prone than two other Asian ethnic groups (Malays and Chinese) to develop central obesity (the reason for which is not clear) with insulin resistance, hyperinsulinaemia, and glucose intolerance. This leads to some but not all of the features of syndrome X, with lower HDL cholesterol and higher PAI-1 levels. In addition, Indians have higher \( Lp(a) \) levels. Whether or not all this can fully explain the much greater susceptibility of Indians to CHD is not clear and other possible reasons have been investigated in the National University of Singapore heart study.

Funding: The National University of Singapore and National Medical Research Council. Conflicts of interest: none.
Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore.

K Hughes, T C Aw, P Kuperan and M Choo

*J Epidemiol Community Health* 1997 51: 394-399
doi: 10.1136/jech.51.4.394

Updated information and services can be found at:
http://jech.bmj.com/content/51/4/394

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/